



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 12/02/2022 06:00  
**Last Report Issued** 06/27/2022 14:35

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2532B  
**Patient ID** 2532B  
**Chain** 22001669  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 22001669  
**Received** 06/24/2022

**Lab ID** 22001669-001  
**Matrix** Blood  
**Patient Name** 2532B  
**Patient ID** 2532B  
**Container Type** Lavender (Purple) Cap Glass Tube

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Results were removed from report on 06/27/2022.

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2532B Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Teriflunomide (Pre-Pregnancy)	None Detected	ng/mL	5.0	
-------------------------------	---------------	-------	-----	--

Synonym(s): Leflunomide Metabolite

Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is a metabolite of leflunomide.

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL.

The blood to plasma ratio is 0.5 to 0.7.

The drug carries a black box warning for hepatotoxicity and pregnancy.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.